How Metformin Works—and Why It Does More Than Expected
Metformin is the world's most prescribed diabetes drug, taken by over 150 million people yearly. Scientists are still uncovering how it works, including a recently discovered brain pathway that challenges decades of assumptions.
A 60-Year-Old Drug With Unsolved Mysteries
Metformin is the most prescribed oral diabetes medication on the planet. More than 150 million people take it each year, and in the United States alone it accounts for over 85 million annual prescriptions. The World Health Organization lists it as an essential medicine. Yet after six decades of clinical use, scientists are still piecing together exactly how it works.
Derived from compounds found in Galega officinalis—a European plant known as goat's rue—metformin was first described in the scientific literature in 1922. Its blood-sugar-lowering properties were noted in animal studies in 1929, but the finding was overshadowed by insulin. It finally entered clinical use in France in 1957 and wasn't approved in the United States until 1995.
The Textbook Explanation
For decades, the standard account went like this: metformin works primarily in the liver, where it reduces glucose production. It does this partly by activating an enzyme called AMP-activated protein kinase (AMPK), a master metabolic switch that senses low energy in cells and adjusts their behavior accordingly. Metformin also inhibits mitochondrial respiration, reduces intestinal absorption of glucose, and improves insulin sensitivity in muscle and fat tissue.
But that neat summary always had gaps. Researchers noticed that a delayed-release formulation of metformin—one that stays largely in the gut and barely enters the bloodstream—lowers blood sugar just as effectively as the standard version. That finding hinted that the gut, not just the liver, plays a central role. Meanwhile, other studies pointed to AMPK-independent pathways, lysosomal mechanisms, and changes to the gut microbiome.
A Hidden Pathway in the Brain
Research from Baylor College of Medicine and international collaborators has added another layer of complexity. The team found that metformin acts on a specific region of the brain called the ventromedial hypothalamus (VMH), a structure known to regulate energy balance and glucose metabolism.
Inside the VMH, metformin deactivates a protein called Rap1 and in turn activates a population of neurons known as SF1 neurons. When the researchers injected tiny amounts of metformin directly into the brains of diabetic mice, blood sugar dropped significantly—even at doses thousands of times smaller than a standard oral dose. Conversely, when Rap1 was kept artificially active in the brain, metformin lost much of its glucose-lowering power.
The discovery, published in Science Advances, suggests that the brain is not merely a bystander but an active participant in metformin's therapeutic effects.
Beyond Blood Sugar
Metformin's reach extends well past diabetes management. Epidemiological studies have found that diabetic patients taking metformin show lower rates of several cancers—particularly pancreatic, liver, and colon cancers—compared with those on other glucose-lowering drugs. Laboratory research points to metformin's ability to suppress the mTOR pathway, stimulate autophagy (the cell's internal cleanup process), and reduce chronic inflammation linked to cellular aging.
Animal studies have been striking. Metformin extends the lifespan of roundworms by up to 50 percent, and positive effects on longevity have been observed in flies, mice, and rats. These findings helped inspire the TAME (Targeting Aging with Metformin) trial, a landmark clinical study designed to enroll 3,000 adults aged 65 to 79. Its goal is to test whether metformin can delay the onset of multiple age-related diseases simultaneously—a first in geroscience. The trial, led by aging researcher Nir Barzilai and now managed through ARPA-H, has faced repeated funding delays but remains one of the most closely watched studies in longevity science.
Cheap, Old, and Still Surprising
At roughly four cents per pill in generic form, metformin is one of the least expensive medications in modern pharmacology. Its safety profile over six decades of use is well established, with gastrointestinal side effects being the most common complaint. The combination of low cost, broad availability, and an expanding portfolio of potential benefits makes it a unique object of scientific interest.
What remains clear is that after more than 60 years, the world's most popular diabetes drug still has secrets to reveal. Each new discovery—from gut-based mechanisms to brain pathways—underscores how much remains unknown about one of medicine's most familiar molecules.
